RT @synovialjoints: PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs…
Tweet Content
PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On